Idiopathic Multicentric Castleman Disease

• EMA approval · 2026-03-24
  EMA Authorised: Sylvant (siltuximab) — Recordati Netherlands B.V.

  The European Medicines Agency has authorized Sylvant (siltuximab) for giant lymph node hyperplasia (Castleman disease) with accelerated asse…

• FDA approval · 2014-04-23
  FDA Approved: SYLVANT — Original Application (Recordati Rare Diseases, Inc.)

  The FDA approved Sylvant (siltuximab) under the original application by Recordati Rare Diseases, Inc. for idiopathic multicentric Castleman …